Industry
Featured experience
Endo $6.7 billion merger with Mallinckrodt
We are advising Endo on the transaction
GSK up to $1.15 billion acquisition of IDRx
We are advising GSK on the transaction
Charles River Laboratories cooperation agreement with Elliott
We are advising Charles River on the agreement
Galderma Group CHF2.3 billion ($2.6 billion) IPO
We advised Galderma on its IPO
Royalty Pharma $2.5 billion IPO
Davis Polk advised Royalty Pharma plc and the selling shareholders on Royalty Pharma’s $2.5 billion initial public offering…
Generation Bio $230 million IPO
Davis Polk advised the representatives of the underwriters in connection with the $230 million initial public offering…
Applied Therapeutics $100 million at-the-market offering
Davis Polk advised the sales agent in connection with an SEC-registered at-the-market offering by Applied Therapeutics,…
ChemoCentryx $346.8 million follow-on offering
Davis Polk advised the representatives of the several underwriters in connection with the SEC-registered offering of 5…
Jazz Pharmaceuticals $850 million exchangeable senior notes offering
Davis Polk advised the initial purchasers on a Rule 144A offering by Jazz Investments I Limited, a wholly owned…
Novo Nordisk $725 million acquisition of Corvidia Therapeutics
Davis Polk is advising Novo Nordisk A/S on its acquisition of Corvidia Therapeutics Inc. for an upfront payment of $725…
Legend Biotech $487 million IPO
Davis Polk advised the underwriters in connection with the $487 million SEC-registered initial public offering by Legend…
Humanigen $72 million stock PIPE offering
Davis Polk advised the placement agent in connection with a private placement pursuant to Rule 4(a)(2) by Humanigen Inc…
Atara Biotherapeutics $175 million stock and pre-funded warrants offering
Davis Polk advised the joint book-running managers and representatives of the several underwriters in connection with a $175…
NuVasive $400 million convertible senior notes offering
Davis Polk advised the representatives of the initial purchasers in connection with a Rule 144A offering by NuVasive,…